2013 commercial formulary changes

Effective Jan. 1, 2013, certain drugs under the Humana commercial formularies will have new limitations or will require utilization management for the 2013 plan year. These changes could mean higher costs or new requirements for Humana members who choose to use these drugs. Humana encourages the use of generic and cost-effective brand medications whenever possible.

Below is a list of some commonly used medications that will be impacted by Humana commercial formulary changes in 2013 [i.e., prior authorization (PA) requirements and step therapy (ST) modifications]. Humana members are asked to talk to their health care provider about possible alternatives.

Download and print a PDF file of this information.

Impacted Drug

2013 Formularies

One Possible Alternative

Rx3

Rx4

Actos

ST

ST

pioglitazone

Actoplus Met

ST

ST

pioglitazone/metformin

Asacol/Asacol HD

ST

ST

Apriso

Boniva

ST

ST

ibandronate

Clarinex

ST

ST

desloratadine

Diovan

ST

ST

valsartan

Diovan HCT

ST

ST

valsartan/HCTZ

Exalgo

ST

ST

morphine sulfate ER

Fortamet

ST

ST

metformin

Lexapro

ST

ST

escitalopram

Maxair Autohaler

ST

ST

Ventolin HFA

Maxalt

ST

ST

rizatriptan

Naprelan

ST

ST

naproxen

Plavix

ST

ST

clopidogrel

ribavirin

PA

PA

n/a

Rythmol SR

ST

ST

propafenone ER

Seroquel

ST

ST

quetiapine

Singulair

ST

ST

montelukast

Uroxatral

ST

ST

alfuzosin ER

Xifaxan

PA

PA

n/a

For prescription drug information for Humana commercial members, visit our website at www.humana.com/providers/pharmacy/drug_list.aspx. Click "Drug List Search" and enter the drug name. Choose "Commercial" to see the drug’s tier placement in commercial formularies and any restrictions that apply.

If you have any questions regarding this document, please call 1-800-457-4708. This line is open from 8 a.m. to 8 p.m., local time, Monday through Friday. (In Puerto Rico, please call 1-866-773-5959.)